Search

Your search keyword '"Wargo, Jennifer"' showing total 1,792 results
Start Over Author "Wargo, Jennifer"
1,792 results on '"Wargo, Jennifer"'

1. A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma

Author

Roland, Christina L., Nassif Haddad, Elise F., Keung, Emily Z., Wang, Wei-Lien, Lazar, Alexander J., Lin, Heather, Chelvanambi, Manoj, Parra, Edwin R., Wani, Khalida, Guadagnolo, B. Ashleigh, Bishop, Andrew J., Burton, Elizabeth M., Hunt, Kelly K., Torres, Keila E., Feig, Barry W., Scally, Christopher P., Lewis, Valerae O., Bird, Justin E., Ratan, Ravin, Araujo, Dejka, Zarzour, M. Alexandra, Patel, Shreyaskumar, Benjamin, Robert, Conley, Anthony P., Livingston, J. Andrew, Ravi, Vinod, Tawbi, Hussein A., Lin, Patrick P., Moon, Bryan S., Satcher, Robert L., Mujtaba, Bilal, Witt, Russell G., Traweek, Raymond S., Cope, Brandon, Lazcano, Rossana, Wu, Chia-Chin, Zhou, Xiao, Mohammad, Mohammad M., Chu, Randy A., Zhang, Jianhua, Damania, Ashish, Sahasrabhojane, Pranoti, Tate, Taylor, Callahan, Kate, Nguyen, Sa, Ingram, Davis, Morey, Rohini, Crosby, Shadarra, Mathew, Grace, Duncan, Sheila, Lima, Cibelle F., Blay, Jean-Yves, Fridman, Wolf Herman, Shaw, Kenna, Wistuba, Ignacio, Futreal, Andrew, Ajami, Nadim, Wargo, Jennifer A., and Somaiah, Neeta

Published
2024
Full Text
View/download PDF

3. Author Correction: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results

Author

Glitza Oliva, Isabella C., Ferguson, Sherise D., Bassett, Jr, Roland, Foster, Alexandra P., John, Ida, Hennegan, Tarin D., Rohlfs, Michelle, Richard, Jessie, Iqbal, Masood, Dett, Tina, Lacey, Carol, Jackson, Natalie, Rodgers, Theresa, Phillips, Suzanne, Duncan, Sheila, Haydu, Lauren, Lin, Ruitao, Amaria, Rodabe N., Wong, Michael K., Diab, Adi, Yee, Cassian, Patel, Sapna P., McQuade, Jennifer L., Fischer, Grant M., McCutcheon, Ian E., O’Brien, Barbara J., Tummala, Sudhakar, Debnam, Matthew, Guha-Thakurta, Nandita, Wargo, Jennifer A., Carapeto, Fernando C. L., Hudgens, Courtney W., Huse, Jason T., Tetzlaff, Michael T., Burton, Elizabeth M., Tawbi, Hussein A., and Davies, Michael A.

Published
2024
Full Text
View/download PDF

4. Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells

Author

Goyal, Yogesh, Busch, Gianna T., Pillai, Maalavika, Li, Jingxin, Boe, Ryan H., Grody, Emanuelle I., Chelvanambi, Manoj, Dardani, Ian P., Emert, Benjamin, Bodkin, Nicholas, Braun, Jonas, Fingerman, Dylan, Kaur, Amanpreet, Jain, Naveen, Ravindran, Pavithran T., Mellis, Ian A., Kiani, Karun, Alicea, Gretchen M., Fane, Mitchell E., Ahmed, Syeda Subia, Li, Haiyin, Chen, Yeqing, Chai, Cedric, Kaster, Jessica, Witt, Russell G., Lazcano, Rossana, Ingram, Davis R., Johnson, Sarah B., Wani, Khalida, Dunagin, Margaret C., Lazar, Alexander J., Weeraratna, Ashani T., Wargo, Jennifer A., Herlyn, Meenhard, and Raj, Arjun

Published
2023
Full Text
View/download PDF

7. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results

Author

Glitza Oliva, Isabella C., Ferguson, Sherise D., Bassett, Jr, Roland, Foster, Alexandra P., John, Ida, Hennegan, Tarin D., Rohlfs, Michelle, Richard, Jessie, Iqbal, Masood, Dett, Tina, Lacey, Carol, Jackson, Natalie, Rodgers, Theresa, Phillips, Suzanne, Duncan, Sheila, Haydu, Lauren, Lin, Ruitao, Amaria, Rodabe N., Wong, Michael K., Diab, Adi, Yee, Cassian, Patel, Sapna P., McQuade, Jennifer L., Fischer, Grant M., McCutcheon, Ian E., O’Brien, Barbara J., Tummala, Sudhakar, Debnam, Matthew, Guha-Thakurta, Nandita, Wargo, Jennifer A., Carapeto, Fernando C. L., Hudgens, Courtney W., Huse, Jason T., Tetzlaff, Michael T., Burton, Elizabeth M., Tawbi, Hussein A., and Davies, Michael A.

Published
2023
Full Text
View/download PDF

8. Embracing cancer complexity: Hallmarks of systemic disease

Author

Swanton, Charles, Bernard, Elsa, Abbosh, Chris, André, Fabrice, Auwerx, Johan, Balmain, Allan, Bar-Sagi, Dafna, Bernards, René, Bullman, Susan, DeGregori, James, Elliott, Catherine, Erez, Ayelet, Evan, Gerard, Febbraio, Mark A., Hidalgo, Andrés, Jamal-Hanjani, Mariam, Joyce, Johanna A., Kaiser, Matthew, Lamia, Katja, Locasale, Jason W., Loi, Sherene, Malanchi, Ilaria, Merad, Miriam, Musgrave, Kathryn, Patel, Ketan J., Quezada, Sergio, Wargo, Jennifer A., Weeraratna, Ashani, White, Eileen, Winkler, Frank, Wood, John N., Vousden, Karen H., and Hanahan, Douglas

Published
2024
Full Text
View/download PDF

9. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

Author

Cascone, Tina, Leung, Cheuk H., Weissferdt, Annikka, Pataer, Apar, Carter, Brett W., Godoy, Myrna C. B., Feldman, Hope, William, Jr, William N., Xi, Yuanxin, Basu, Sreyashi, Sun, Jing Jing, Yadav, Shalini S., Rojas Alvarez, Frank R., Lee, Younghee, Mishra, Aditya K., Chen, Lili, Pradhan, Monika, Guo, Haiping, Sinjab, Ansam, Zhou, Nicolas, Negrao, Marcelo V., Le, Xiuning, Gay, Carl M., Tsao, Anne S., Byers, Lauren Averett, Altan, Mehmet, Glisson, Bonnie S., Fossella, Frank V., Elamin, Yasir Y., Blumenschein, Jr, George, Zhang, Jianjun, Skoulidis, Ferdinandos, Wu, Jia, Mehran, Reza J., Rice, David C., Walsh, Garrett L., Hofstetter, Wayne L., Rajaram, Ravi, Antonoff, Mara B., Fujimoto, Junya, Solis, Luisa M., Parra, Edwin R., Haymaker, Cara, Wistuba, Ignacio I., Swisher, Stephen G., Vaporciyan, Ara A., Lin, Heather Y., Wang, Jing, Gibbons, Don L., Jack Lee, J., Ajami, Nadim J., Wargo, Jennifer A., Allison, James P., Sharma, Padmanee, Kadara, Humam, Heymach, John V., and Sepesi, Boris

Published
2023
Full Text
View/download PDF

10. Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy

Author

Lester, Daniel K., Burton, Chase, Gardner, Alycia, Innamarato, Patrick, Kodumudi, Krithika, Liu, Qian, Adhikari, Emma, Ming, Qianqian, Williamson, Daniel B., Frederick, Dennie T., Sharova, Tatyana, White, Michael G., Markowitz, Joseph, Cao, Biwei, Nguyen, Jonathan, Johnson, Joseph, Beatty, Matthew, Mockabee-Macias, Andrea, Mercurio, Matthew, Watson, Gregory, Chen, Pei-Ling, McCarthy, Susan, MoranSegura, Carlos, Messina, Jane, Thomas, Kerry L., Darville, Lancia, Izumi, Victoria, Koomen, John M., Pilon-Thomas, Shari A., Ruffell, Brian, Luca, Vincent C., Haltiwanger, Robert S., Wang, Xuefeng, Wargo, Jennifer A., Boland, Genevieve M., and Lau, Eric K.

Published
2023
Full Text
View/download PDF

11. Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1.

Author

Lu, Yue, Ng, Alphonsus HC, Chow, Frances E, Everson, Richard G, Helmink, Beth A, Tetzlaff, Michael T, Thakur, Rohit, Wargo, Jennifer A, Cloughesy, Timothy F, Prins, Robert M, and Heath, James R

Subjects
CD8-Positive T-Lymphocytes, Humans, Glioblastoma, Melanoma, Brain Neoplasms, Neoplasm Recurrence, Local, Treatment Outcome, Neoadjuvant Therapy, Adult, Aged, Middle Aged, Female, Male, Tumor Microenvironment, CTLA-4 Antigen, Programmed Cell Death 1 Receptor, Biomarkers, Tumor, Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Immune Checkpoint Inhibitors, Rare Diseases, Brain Disorders, Brain Cancer, Cancer, Neurosciences
Abstract

The response of patients with recurrent glioblastoma multiforme to neoadjuvant immune checkpoint blockade has been challenging to interpret due to the inter-patient and intra-tumor heterogeneity. We report on a comparative analysis of tumor tissues collected from patients with recurrent glioblastoma and high-risk melanoma, both treated with neoadjuvant checkpoint blockade. We develop a framework that uses multiplex spatial protein profiling, machine learning-based image analysis, and data-driven computational models to investigate the pathophysiological and molecular factors within the tumor microenvironment that influence treatment response. Using melanoma to guide the interpretation of glioblastoma analyses, we interrogate the protein expression in microscopic compartments of tumors, and determine the correlates of cytotoxic CD8+ T cells, tumor growth, treatment response, and immune cell-cell interaction. This work reveals similarities shared between glioblastoma and melanoma, immunosuppressive factors that are unique to the glioblastoma microenvironment, and potential co-targets for enhancing the efficacy of neoadjuvant immune checkpoint blockade.

Published
2021

12. Modulating a prebiotic food source influences inflammation and immune-regulating gut microbes and metabolites: insights from the BE GONE trial

Author

Zhang, Xiaotao, Irajizad, Ehsan, Hoffman, Kristi L., Fahrmann, Johannes F., Li, Fangyu, Seo, Yongwoo David, Browman, Gladys J., Dennison, Jennifer B., Vykoukal, Jody, Luna, Pamela N., Siu, Wesley, Wu, Ranran, Murage, Eunice, Ajami, Nadim J., McQuade, Jennifer L., Wargo, Jennifer A., Long, James P., Do, Kim-Anh, Lampe, Johanna W., Basen-Engquist, Karen M., Okhuysen, Pablo C., Kopetz, Scott, Hanash, Samir M., Petrosino, Joseph F., Scheet, Paul, and Daniel, Carrie R.

Published
2023
Full Text
View/download PDF

13. Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring

Author

Colbert, Lauren E., El Alam, Molly B., Wang, Rui, Karpinets, Tatiana, Lo, David, Lynn, Erica J., Harris, Timothy A., Elnaggar, Jacob H., Yoshida-Court, Kyoko, Tomasic, Katarina, Bronk, Julianna K., Sammouri, Julie, Yanamandra, Ananta V., Olvera, Adilene V., Carlin, Lily G., Sims, Travis, Delgado Medrano, Andrea Y., Napravnik, Tatiana Cisneros, O’Hara, Madison, Lin, Daniel, Abana, Chike O., Li, Hannah X., Eifel, Patricia J., Jhingran, Anuja, Joyner, Melissa, Lin, Lilie, Ramondetta, Lois M., Futreal, Andrew M., Schmeler, Kathleen M., Mathew, Geena, Dorta-Estremera, Stephanie, Zhang, Jianhua, Wu, Xiaogang, Ajami, Nadim J., Wong, Matthew, Taniguchi, Cullen, Petrosino, Joseph F., Sastry, K. Jagannadha, Okhuysen, Pablo C., Martinez, Sara A., Tan, Lin, Mahmud, Iqbal, Lorenzi, Philip L., Wargo, Jennifer A., and Klopp, Ann H.

Published
2023
Full Text
View/download PDF

14. English Teaching as an Evangelical Tool for Two-by-Two Missionaries

Author

Wargo, Jennifer

Abstract

Purpose: The purpose of this narrative is to share insights on the little-known two-by-two evangelical sect, specifically its use of English teaching in South Korea and China as a missionary tool of conversion. Design/methodology/approach: This narrative is written in memoir-style, with sections that analyze the author's experiences. The analysis looks at the two-by-two sect through the lens of Gee's Theory of Discourse. Findings: Based on the author's experiences as an insider for 35 years in the two-by-two evangelical sect, four of those in China and S. Korea, she discusses the use of English teaching as a missionary tool of conversion. The paper questions the ethicality of this practice. Practical implications: The author suggests that global English teachers should carefully examine their own religiosity to make sure they are not ethically compromising opportunities for their students in an effort to create converts. Originality/value: This paper sheds light on the global nature of the two-by-two sect, a religion that has very little written about it in the scholarly realm.

Published
2022
Full Text
View/download PDF

15. The microbiome and human cancer

Author

Sepich-Poore, Gregory D, Zitvogel, Laurence, Straussman, Ravid, Hasty, Jeff, Wargo, Jennifer A, and Knight, Rob

Subjects
Human Genome, Cancer, Genetics, 2.1 Biological and endogenous factors, Aetiology, Adaptive Immunity, Anti-Bacterial Agents, Antineoplastic Agents, Bacteria, Bacterial Physiological Phenomena, Carcinogenesis, Gastrointestinal Microbiome, Genetic Engineering, Host Microbial Interactions, Humans, Immunomodulation, Immunotherapy, Lymphoid Tissue, Microbiota, Neoplasms, Oncolytic Virotherapy, Tumor Microenvironment, Virus Physiological Phenomena, General Science & Technology
Abstract

Microbial roles in cancer formation, diagnosis, prognosis, and treatment have been disputed for centuries. Recent studies have provocatively claimed that bacteria, viruses, and/or fungi are pervasive among cancers, key actors in cancer immunotherapy, and engineerable to treat metastases. Despite these findings, the number of microbes known to directly cause carcinogenesis remains small. Critically evaluating and building frameworks for such evidence in light of modern cancer biology is an important task. In this Review, we delineate between causal and complicit roles of microbes in cancer and trace common themes of their influence through the host's immune system, herein defined as the immuno-oncology-microbiome axis. We further review evidence for intratumoral microbes and approaches that manipulate the host's gut or tumor microbiome while projecting the next phase of experimental discovery.

Published
2021

16. Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy.

Author

Somasundaram, Rajasekharan, Connelly, Thomas, Choi, Robin, Choi, Hyeree, Samarkina, Anastasia, Li, Ling, Gregorio, Elizabeth, Chen, Yeqing, Thakur, Rohit, Abdel-Mohsen, Mohamed, Beqiri, Marilda, Kiernan, Meaghan, Perego, Michela, Wang, Fang, Xiao, Min, Brafford, Patricia, Yang, Xue, Xu, Xiaowei, Secreto, Anthony, Danet-Desnoyers, Gwenn, Traum, Daniel, Kaestner, Klaus H, Huang, Alexander C, Hristova, Denitsa, Wang, Joshua, Fukunaga-Kalabis, Mizuho, Krepler, Clemens, Ping-Chen, Fang, Zhou, Xiangyang, Gutierrez, Alexis, Rebecca, Vito W, Vonteddu, Prashanthi, Dotiwala, Farokh, Bala, Shashi, Majumdar, Sonali, Dweep, Harsh, Wickramasinghe, Jayamanna, Kossenkov, Andrew V, Reyes-Arbujas, Jorge, Santiago, Kenisha, Nguyen, Tran, Griss, Johannes, Keeney, Frederick, Hayden, James, Gavin, Brian J, Weiner, David, Montaner, Luis J, Liu, Qin, Peiffer, Lukas, Becker, Jürgen, Burton, Elizabeth M, Davies, Michael A, Tetzlaff, Michael T, Muthumani, Kar, Wargo, Jennifer A, Gabrilovich, Dmitry, and Herlyn, Meenhard

Subjects
B-Lymphocytes, T-Lymphocytes, Lymphocytes, Tumor-Infiltrating, Mast Cells, Animals, Mice, Transgenic, Humans, Melanoma, Drug Resistance, Neoplasm, Programmed Cell Death 1 Receptor, Sunitinib, Immune Checkpoint Inhibitors
Abstract

Anti-PD-1 therapy is used as a front-line treatment for many cancers, but mechanistic insight into this therapy resistance is still lacking. Here we generate a humanized (Hu)-mouse melanoma model by injecting fetal liver-derived CD34+ cells and implanting autologous thymus in immune-deficient NOD-scid IL2Rγnull (NSG) mice. Reconstituted Hu-mice are challenged with HLA-matched melanomas and treated with anti-PD-1, which results in restricted tumor growth but not complete regression. Tumor RNA-seq, multiplexed imaging and immunohistology staining show high expression of chemokines, as well as recruitment of FOXP3+ Treg and mast cells, in selective tumor regions. Reduced HLA-class I expression and CD8+/Granz B+ T cells homeostasis are observed in tumor regions where FOXP3+ Treg and mast cells co-localize, with such features associated with resistance to anti-PD-1 treatment. Combining anti-PD-1 with sunitinib or imatinib results in the depletion of mast cells and complete regression of tumors. Our results thus implicate mast cell depletion for improving the efficacy of anti-PD-1 therapy.

Published
2021

20. Neoadjuvant relatlimab and nivolumab in resectable melanoma

Author

Amaria, Rodabe N., Postow, Michael, Burton, Elizabeth M., Tezlaff, Michael T., Ross, Merrick I., Torres-Cabala, Carlos, Glitza, Isabella C., Duan, Fei, Milton, Denái R., Busam, Klaus, Simpson, Lauren, McQuade, Jennifer L., Wong, Michael K., Gershenwald, Jeffrey E., Lee, Jeffrey E., Goepfert, Ryan P., Keung, Emily Z., Fisher, Sarah B., Betof-Warner, Allison, Shoushtari, Alexander N., Callahan, Margaret, Coit, Daniel, Bartlett, Edmund K., Bello, Danielle, Momtaz, Parisa, Nicholas, Courtney, Gu, Aidi, Zhang, Xuejun, Korivi, Brinda Rao, Patnana, Madhavi, Patel, Sapna P., Diab, Adi, Lucci, Anthony, Prieto, Victor G., Davies, Michael A., Allison, James P., Sharma, Padmanee, Wargo, Jennifer A., Ariyan, Charlotte, and Tawbi, Hussein A.

Published
2022
Full Text
View/download PDF

21. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome

Author

Simpson, Rebecca C., Shanahan, Erin R., Batten, Marcel, Reijers, Irene L. M., Read, Mark, Silva, Ines P., Versluis, Judith M., Ribeiro, Rosilene, Angelatos, Alexandra S., Tan, Jian, Adhikari, Chandra, Menzies, Alexander M., Saw, Robyn P. M., Gonzalez, Maria, Shannon, Kerwin F., Spillane, Andrew J., Velickovic, Rebecca, Lazar, Alexander J., Damania, Ashish V., Mishra, Aditya K., Chelvanambi, Manoj, Banerjee, Anik, Ajami, Nadim J., Wargo, Jennifer A., Macia, Laurence, Holmes, Andrew J., Wilmott, James S., Blank, Christian U., Scolyer, Richard A., and Long, Georgina V.

Published
2022
Full Text
View/download PDF

23. B cells and tertiary lymphoid structures promote immunotherapy response

Author

Helmink, Beth A, Reddy, Sangeetha M, Gao, Jianjun, Zhang, Shaojun, Basar, Rafet, Thakur, Rohit, Yizhak, Keren, Sade-Feldman, Moshe, Blando, Jorge, Han, Guangchun, Gopalakrishnan, Vancheswaran, Xi, Yuanxin, Zhao, Hao, Amaria, Rodabe N, Tawbi, Hussein A, Cogdill, Alex P, Liu, Wenbin, LeBleu, Valerie S, Kugeratski, Fernanda G, Patel, Sapna, Davies, Michael A, Hwu, Patrick, Lee, Jeffrey E, Gershenwald, Jeffrey E, Lucci, Anthony, Arora, Reetakshi, Woodman, Scott, Keung, Emily Z, Gaudreau, Pierre-Olivier, Reuben, Alexandre, Spencer, Christine N, Burton, Elizabeth M, Haydu, Lauren E, Lazar, Alexander J, Zapassodi, Roberta, Hudgens, Courtney W, Ledesma, Deborah A, Ong, SuFey, Bailey, Michael, Warren, Sarah, Rao, Disha, Krijgsman, Oscar, Rozeman, Elisa A, Peeper, Daniel, Blank, Christian U, Schumacher, Ton N, Butterfield, Lisa H, Zelazowska, Monika A, McBride, Kevin M, Kalluri, Raghu, Allison, James, Petitprez, Florent, Fridman, Wolf Herman, Sautès-Fridman, Catherine, Hacohen, Nir, Rezvani, Katayoun, Sharma, Padmanee, Tetzlaff, Michael T, Wang, Linghua, and Wargo, Jennifer A

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Immunization, Cancer, Vaccine Related, Genetics, B-Lymphocytes, Biomarkers, Tumor, Carcinoma, Renal Cell, Cell Cycle Checkpoints, Clone Cells, Dendritic Cells, Follicular, Gene Expression Regulation, Neoplastic, Humans, Immunologic Memory, Immunotherapy, Mass Spectrometry, Melanoma, Neoplasm Metastasis, Phenotype, Prognosis, RNA-Seq, Receptors, Immunologic, Single-Cell Analysis, T-Lymphocytes, Tertiary Lymphoid Structures, Transcriptome, General Science & Technology
Abstract

Treatment with immune checkpoint blockade (ICB) has revolutionized cancer therapy. Until now, predictive biomarkers1-10 and strategies to augment clinical response have largely focused on the T cell compartment. However, other immune subsets may also contribute to anti-tumour immunity11-15, although these have been less well-studied in ICB treatment16. A previously conducted neoadjuvant ICB trial in patients with melanoma showed via targeted expression profiling17 that B cell signatures were enriched in the tumours of patients who respond to treatment versus non-responding patients. To build on this, here we performed bulk RNA sequencing and found that B cell markers were the most differentially expressed genes in the tumours of responders versus non-responders. Our findings were corroborated using a computational method (MCP-counter18) to estimate the immune and stromal composition in this and two other ICB-treated cohorts (patients with melanoma and renal cell carcinoma). Histological evaluation highlighted the localization of B cells within tertiary lymphoid structures. We assessed the potential functional contributions of B cells via bulk and single-cell RNA sequencing, which demonstrate clonal expansion and unique functional states of B cells in responders. Mass cytometry showed that switched memory B cells were enriched in the tumours of responders. Together, these data provide insights into the potential role of B cells and tertiary lymphoid structures in the response to ICB treatment, with implications for the development of biomarkers and therapeutic targets.

Published
2020

26. Bridging the research-practice gap in education: Initiatives from 3 OECD countries.

Author

Schlicht-Schmälzle, Raphaela, Hill, Jordan, Folkvord, Kåre Andreas, Tharaldsen, Kjersti Balle, Wargo, Jennifer, Hartmann, Ulrike, and Révai, Nóra

Subjects
RESEARCH-practice gap, EDUCATION, PARTNERSHIPS in education, EDUCATION research, RESEARCH
Abstract

Over the past two decades, the use of research in educational practice has emerged as a policy imperative in many OECD countries. However, concerns about the significant gap between research evidence and practice are persistent. This working paper delves into the role of research-practice partnerships in bridging this persistent divide. It critically evaluates common assumptions associated with such partnerships through an overview of research, insights from recent OECD data, and importantly, through three in-depth case studies. The case studies illustrate partnerships between education researchers and school practitioners in three contexts: Norway, the United States, and Germany. They examine the conditions under which these can achieve an impact on both research and practice and illuminate challenges and open questions associated with these collaborations. The paper aims to inform policy makers and researchers alike on the potential and limitations of research-practice partnerships. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Author

Vellano, Christopher P., White, Michael G., Andrews, Miles C., Chelvanambi, Manoj, Witt, Russell G., Daniele, Joseph R., Titus, Mark, McQuade, Jennifer L., Conforti, Fabio, Burton, Elizabeth M., Lastrapes, Matthew J., Ologun, Gabriel, Cogdill, Alexandria P., Morad, Golnaz, Prieto, Peter, Lazar, Alexander J., Chu, Yanshuo, Han, Guangchun, Khan, M. A. Wadud, Helmink, Beth, Davies, Michael A., Amaria, Rodabe N., Kovacs, Jeffrey J., Woodman, Scott E., Patel, Sapna, Hwu, Patrick, Peoples, Michael, Lee, Jeffrey E., Cooper, Zachary A., Zhu, Haifeng, Gao, Guang, Banerjee, Hiya, Lau, Mike, Gershenwald, Jeffrey E., Lucci, Anthony, Keung, Emily Z., Ross, Merrick I., Pala, Laura, Pagan, Eleonora, Segura, Rossana Lazcano, Liu, Qian, Borthwick, Mikayla S., Lau, Eric, Yates, Melinda S., Westin, Shannon N., Wani, Khalida, Tetzlaff, Michael T., Haydu, Lauren E., Mahendra, Mikhila, Ma, XiaoYan, Logothetis, Christopher, Kulstad, Zachary, Johnson, Sarah, Hudgens, Courtney W., Feng, Ningping, Federico, Lorenzo, Long, Georgina V., Futreal, P. Andrew, Arur, Swathi, Tawbi, Hussein A., Moran, Amy E., Wang, Linghua, Heffernan, Timothy P., Marszalek, Joseph R., and Wargo, Jennifer A.

Published
2022
Full Text
View/download PDF

30. Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

Author

van Akkooi, Alexander C. J., Hieken, Tina J., Burton, Elizabeth M., Ariyan, Charlotte, Ascierto, Paolo A., Asero, Salvatore V. M. A., Blank, Christian U., Block, Matthew S., Boland, Genevieve M., Caraco, Corrado, Chng, Sydney, Davidson, B. Scott, Duprat Neto, Joao Pedreira, Faries, Mark B., Gershenwald, Jeffrey E., Grunhagen, Dirk J., Gyorki, David E., Han, Dale, Hayes, Andrew J., van Houdt, Winan J., Karakousis, Giorgos C., Klop, Willem M. C., Long, Georgina V., Lowe, Michael C., Menzies, Alexander M., Olofsson Bagge, Roger, Pennington, Thomas E., Rutkowski, Piotr, Saw, Robyn P. M., Scolyer, Richard A., Shannon, Kerwin F., Sondak, Vernon K., Tawbi, Hussein, Testori, Alessandro A. E., Tetzlaff, Mike T., Thompson, John F., Zager, Jonathan S., Zuur, Charlotte L., Wargo, Jennifer A., Spillane, Andrew J., and Ross, Merrick I.

Published
2022
Full Text
View/download PDF

36. Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1)

Author

Michikawa, Chieko, Gopalakrishnan, Vancheswaran, Harrandah, Amani M., Karpinets, Tatiana V, Garg, Rekha Rani, Chu, Randy A., Park, Yuk Pheel, Chukkapallia, Sasanka S., Yadlapalli, Nikhita, Erikson-Carter, Kelly C., Gleber-Netto, Frederico Omar, Sayour, Elias, Progulske-Fox, Ann, Chan, ‏Edward K.L., Wu, Xiaogang, Zhang, Jianhua, Jobin, Christian, Wargo, Jennifer A., Pickering, Curtis R., Myers, Jeffrey N., and Silver, Natalie

Published
2022
Full Text
View/download PDF

39. Multi-modal molecular programs regulate melanoma cell state

Author

Andrews, Miles C., Oba, Junna, Wu, Chang-Jiun, Zhu, Haifeng, Karpinets, Tatiana, Creasy, Caitlin A., Forget, Marie-Andrée, Yu, Xiaoxing, Song, Xingzhi, Mao, Xizeng, Robertson, A. Gordon, Romano, Gabriele, Li, Peng, Burton, Elizabeth M., Lu, Yiling, Sloane, Robert Szczepaniak, Wani, Khalida M., Rai, Kunal, Lazar, Alexander J., Haydu, Lauren E., Bustos, Matias A., Shen, Jianjun, Chen, Yueping, Morgan, Margaret B., Wargo, Jennifer A., Kwong, Lawrence N., Haymaker, Cara L., Grimm, Elizabeth A., Hwu, Patrick, Hoon, Dave S. B., Zhang, Jianhua, Gershenwald, Jeffrey E., Davies, Michael A., Futreal, P. Andrew, Bernatchez, Chantale, and Woodman, Scott E.

Published
2022
Full Text
View/download PDF

41. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

Author

McQuade, Jennifer L, Daniel, Carrie R, Hess, Kenneth R, Mak, Carmen, Wang, Daniel Y, Rai, Rajat R, Park, John J, Haydu, Lauren E, Spencer, Christine, Wongchenko, Matthew, Lane, Stephen, Lee, Dung-Yang, Kaper, Mathilde, McKean, Meredith, Beckermann, Kathryn E, Rubinstein, Samuel M, Rooney, Isabelle, Musib, Luna, Budha, Nageshwar, Hsu, Jessie, Nowicki, Theodore S, Avila, Alexandre, Haas, Tomas, Puligandla, Maneka, Lee, Sandra, Fang, Shenying, Wargo, Jennifer A, Gershenwald, Jeffrey E, Lee, Jeffrey E, Hwu, Patrick, Chapman, Paul B, Sosman, Jeffrey A, Schadendorf, Dirk, Grob, Jean-Jacques, Flaherty, Keith T, Walker, Dana, Yan, Yibing, McKenna, Edward, Legos, Jeffrey J, Carlino, Matteo S, Ribas, Antoni, Kirkwood, John M, Long, Georgina V, Johnson, Douglas B, Menzies, Alexander M, and Davies, Michael A

Subjects
Clinical Research, Obesity, Cancer, Clinical Trials and Supportive Activities, Nutrition, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Body Mass Index, Female, Humans, Male, Melanoma, Middle Aged, Molecular Targeted Therapy, Progression-Free Survival, Protective Factors, Randomized Controlled Trials as Topic, Retrospective Studies, Risk Assessment, Risk Factors, Skin Neoplasms, Time Factors, Treatment Outcome, Young Adult, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundObesity has been linked to increased mortality in several cancer types; however, the relation between obesity and survival outcomes in metastatic melanoma is unknown. The aim of this study was to examine the association between body-mass index (BMI) and progression-free survival or overall survival in patients with metastatic melanoma who received targeted therapy, immunotherapy, or chemotherapy.MethodsThis retrospective study analysed independent cohorts of patients with metastatic melanoma assigned to treatment with targeted therapy, immunotherapy, or chemotherapy in randomised clinical trials and one retrospective study of patients treated with immunotherapy. Patients were classified according to BMI, following the WHO definitions, as underweight, normal, overweight, or obese. Patients without BMI and underweight patients were excluded. The primary outcomes were the associations between BMI and progression-free survival or overall survival, stratified by treatment type and sex. We did multivariable analyses in the independent cohorts, and combined adjusted hazard ratios in a mixed-effects meta-analysis to provide a precise estimate of the association between BMI and survival outcomes; heterogeneity was assessed with meta-regression analyses. Analyses were done on the predefined intention-to-treat population in the randomised controlled trials and on all patients included in the retrospective study.FindingsThe six cohorts consisted of a total of 2046 patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy between Aug 8, 2006, and Jan 15, 2016. 1918 patients were included in the analysis. Two cohorts containing patients from randomised controlled trials treated with targeted therapy (dabrafenib plus trametinib [n=599] and vemurafenib plus cobimetinib [n=240]), two cohorts containing patients treated with immunotherapy (one randomised controlled trial of ipilimumab plus dacarbazine [n=207] and a retrospective cohort treated with pembrolizumab, nivolumab, or atezolizumab [n=331]), and two cohorts containing patients treated with chemotherapy (two randomised controlled trials of dacarbazine [n=320 and n=221]) were classified according to BMI as normal (694 [36%] patients), overweight (711 [37%]), or obese (513 [27%]). In the pooled analysis, obesity, compared with normal BMI, was associated with improved survival in patients with metastatic melanoma (average adjusted hazard ratio [HR] 0·77 [95% CI 0·66-0·90] for progression-free survival and 0·74 [0·58-0·95] for overall survival). The survival benefit associated with obesity was restricted to patients treated with targeted therapy (HR 0·72 [0·57-0·91] for progression-free survival and 0·60 [0·45-0·79] for overall survival) and immunotherapy (HR 0·75 [0·56-1·00] and 0·64 [0·47-0·86]). No associations were observed with chemotherapy (HR 0·87 [0·65-1·17, pinteraction=0·61] for progression-free survival and 1·03 [0·80-1·34, pinteraction=0·01] for overall survival). The association of BMI with overall survival for patients treated with targeted and immune therapies differed by sex, with inverse associations in men (HR 0·53 [0·40-0·70]), but no associations observed in women (HR 0·85 [0·61-1·18, pinteraction=0·03]).InterpretationOur results suggest that in patients with metastatic melanoma, obesity is associated with improved progression-free survival and overall survival compared with those outcomes in patients with normal BMI, and that this association is mainly seen in male patients treated with targeted or immune therapy. These results have implications for the design of future clinical trials for patients with metastatic melanoma and the magnitude of the benefit found supports further investigation of the underlying mechanism of these associations.FundingASCO/CCF Young Investigator Award, ASCO/CCF Career Development Award, MD Anderson Cancer Center (MDACC) Melanoma Moonshot Program, MDACC Melanoma SPORE, and the Dr Miriam and Sheldon G Adelson Medical Research Foundation.

Published
2018

42. Coenzyme A fuels T cell anti-tumor immunity

Author

St. Paul, Michael, Saibil, Samuel D., Han, SeongJun, Israni-Winger, Kavita, Lien, Scott C., Laister, Rob C., Sayad, Azin, Penny, Susanne, Amaria, Rodabe N., Haydu, Lauren E., Garcia-Batres, Carlos R., Kates, Meghan, Mulder, David T., Robert-Tissot, Céline, Gold, Matthew J., Tran, Charles W., Elford, Alisha R., Nguyen, Linh T., Pugh, Trevor J., Pinto, Devanand M., Wargo, Jennifer A., and Ohashi, Pamela S.

Published
2021
Full Text
View/download PDF

43. Abstract B024: Immune exhaustion and reversal of progestin-related immune modulation in adaptive resistance to levonorgestrel intrauterine device for treatment of atypical hyperplasia and early endometrial cancer

Author

Bowen, Mikayla B., primary, Melendez, Brenda, additional, Zhang, Qian, additional, Yang, Richard, additional, Fellman, Bryan, additional, Lawson, Barrett, additional, Adjei, Naomi, additional, Celestino, Joseph, additional, Nguyen, Tri, additional, Wani, Khalida, additional, Singh, Bhavana, additional, Straub, Christof, additional, Zhang, Liang, additional, Tan, Cheryl, additional, New, Felicia, additional, Urbauer, Diana, additional, Lazar, Alexander, additional, Lu, Karen, additional, Wargo, Jennifer, additional, Westin, Shannon N., additional, and Yates, Melinda S., additional

Published
2024
Full Text
View/download PDF

44. Androgen drives melanoma invasiveness and metastatic spread by inducing tumorigenic fucosylation

Author

Liu, Qian, primary, Adhikari, Emma, additional, Lester, Daniel K., additional, Fang, Bin, additional, Johnson, Joseph O., additional, Tian, Yijun, additional, Mockabee-Macias, Andrea T., additional, Izumi, Victoria, additional, Guzman, Kelly M., additional, White, Michael G., additional, Koomen, John M., additional, Wargo, Jennifer A., additional, Messina, Jane L., additional, Qi, Jianfei, additional, and Lau, Eric K., additional

Published
2024
Full Text
View/download PDF

45. Correlation of cancer testis antigen expression with high type-I interferon signal and prognosis in small bowel neuroendocrine tumors.

Author

Ayabe, Reed I., primary, Seo, Yongwoo David, additional, Melendez, Brenda, additional, Lazcano Segura, Rossana, additional, Fields, Brittany C., additional, Wani, Khalida M., additional, Johnson, Sarah, additional, Witt, Russell, additional, Chelvanambi, Manoj, additional, Hudgens, Courtney, additional, Hernandez, Sharia D., additional, Ajami, Nadim J., additional, Wargo, Jennifer Ann, additional, Lazar, Alexander J., additional, Halperin, Daniel M., additional, Estrella, Jeannelyn, additional, and Maxwell, Jess, additional

Published
2024
Full Text
View/download PDF

46. Tumoral microbial and pathway alterations associated with young-onset rectal cancer and its response to therapy.

Author

White, Michael, primary, Damania, Ashish, additional, Alshenaifi, Jumanah, additional, Sahasrabhojane, Pranoti, additional, Peacock, Oliver, additional, Losh, Jillian, additional, Wong, Matthew C., additional, Berkova, Zuzana, additional, Nguyen, Sa Thi, additional, Chang, George J., additional, Wargo, Jennifer Ann, additional, Ajami, Nadim J., additional, Kopetz, Scott, additional, and You, Y. Nancy, additional

Published
2024
Full Text
View/download PDF

47. Cancer Associated Bacteria in Primary and Metastatic Non-Small Cell Lung Cancer

Author

Thakkar, Krupa, primary, Richard, Corentin, additional, Fu, Hongchang, additional, Simpson, Benjamin S., additional, Cha, Hongui, additional, Augustine, Marcellus, additional, Coulton, Alexander, additional, Castro, Andrea, additional, Veerian, Selvaraju, additional, AbdulJabbar, Khalid, additional, Zhang, Hanyun, additional, Hardas, Alexandros, additional, Al-Sawaf, Othman, additional, Huebner, Arianna, additional, Al-Bakir, Maise, additional, Karasaki, Takahiro, additional, Pich, Oriol, additional, Bailey, Chris, additional, Seo, Yongwoo David, additional, Damania, Ashish, additional, Chelvanambi, Manoj, additional, Ajami, Nadim J., additional, Moore, David, additional, Sivakumar, Monika, additional, Hill, Mark, additional, Frankell, Alexander, additional, Ward, Sophie, additional, Naceur-Lombardelli, Cristina, additional, Salgado, Roberto, additional, Akarca, Ayse, additional, Marafioti, Teresa, additional, McGranahan, Nicholas, additional, Jamal-Hanjani, Mariam, additional, Wargo, Jennifer, additional, Santini, Joanne, additional, Swanton, Charles, additional, and Litchfield, Kevin, additional

Published
2024
Full Text
View/download PDF

50. Neoadjuvant Systemic Therapy for High-Risk Melanoma Patients

Author

Keung, Emily Z., Amaria, Rodabe N., Sondak, Vernon K., Ross, Merrick I., Kirkwood, John M., Wargo, Jennifer A., Balch, Charles M., editor, Atkins, Michael B., editor, Garbe, Claus, editor, Gershenwald, Jeffrey E., editor, Halpern, Allan C., editor, Kirkwood, John M., editor, McArthur, Grant A., editor, Thompson, John F., editor, and Sober, Arthur J., editor

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results